Cardiovascular Genetics Overview

Principles

Definition

Cardiovascular genetics is an academic discipline investigating the influence of genetic variation and inheritance on the structure, function, and diseases of the cardiovascular system. This field seeks to understand the genetic basis of cardiovascular health and pathology to improve diagnosis, risk assessment, and therapeutic strategies.

Ontological type

Key Disorders

Diagnostic Methods

Core Concepts

Key developments

Key Figures

Genetic Epidemiology Foundations era

Stephen E. Epstein [1], associated with Harvard University [2] and Stanford University [3], framed cardiovascular genetics within the Genetic Epidemiology Foundations era. His key contribution is the 1973 paper Familial Prevalence and Genetic Transmission of Idiopathic Hypertrophic Subaortic Stenosis [4], which documented familial prevalence and genetic transmission of IHSS and highlighted heredity's central role in congenital heart disease. This work helped institutionalize family-based methods and quantitative genetics in cardiovascular research, a hallmark of Epstein [1]'s program. In this era, the IHSS study [4] laid a foundational model for genetic risk assessment based on familial aggregation and transmission.

Genotype-Phenotype Translation era

François Cambien [1], Collège de France [3] and Université Paris Cité [4], played a central role in the Genotype-Phenotype Translation era by highlighting how genetic variation shapes cardiovascular traits. His key contribution was the 1990 paper An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels [7], which demonstrated that a common polymorphism can significantly influence a cardiovascular biomarker and thus underpin genotype-phenotype linkage in this era. Florent Soubrier [2], Radboud University Nijmegen [5] and Heidelberg University [6] were central figures in mapping genotype-phenotype relationships in cardiovascular traits during this era. Florent Soubrier [2], co-author of the 1990 paper An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels [7], illustrated how the ACE I/D polymorphism translates to serum enzyme variance and helped catalyze early clinical-genetic testing infrastructures.

Genomics and Polygenic Risk era

Daniel J. Rader [1] is a cardiovascular geneticist associated with Harvard University [3] and the Massachusetts Institute of Technology [4] during this genomics and polygenic risk era. His key contribution in this era includes the identification of a common variant on chromosome 9p21 that affects myocardial infarction risk, as reported in the 2007 paper W2036198235 [6], which helped illuminate polygenic architectures in cardiovascular disease. Christopher B. Granger [2] is affiliated with Stanford University [5] and Harvard University [3] during this era. Granger's contributions center on leveraging the same 9p21 finding from W2036198235 [6] to advance large-scale genetic studies of MI risk and to illustrate the translational potential of genomic risk stratification in diverse populations.